Literature DB >> 1727165

Methylprednisolone or naloxone treatment after acute spinal cord injury: 1-year follow-up data. Results of the second National Acute Spinal Cord Injury Study.

M B Bracken1, M J Shepard, W F Collins, T R Holford, D S Baskin, H M Eisenberg, E Flamm, L Leo-Summers, J C Maroon, L F Marshall.   

Abstract

The 1-year follow-up data of a multicenter randomized controlled trial of methylprednisolone (30 mg/kg bolus and 5.4 mg/kg/hr for 23 hours) or naloxone (5.4 mg/kg bolus and 4.0 mg/kg/hr for 23 hours) treatment for acute spinal cord injury are reported and compared with placebo results. In patients treated with methylprednisolone within 8 hours of injury, increased recovery of neurological function was seen at 6 weeks and at 6 months and continued to be observed 1 year after injury. For motor function, this difference was statistically significant (p = 0.030), and was found in patients with total sensory and motor loss in the emergency room (p = 0.019) and in those with some preservation of motor and sensory function (p = 0.024). Naloxone-treated patients did not show significantly greater recovery. Patients treated after 8 hours of injury recovered less motor function if receiving methylprednisolone (p = 0.08) or naloxone (p = 0.10) as compared with those given placebo. Complication and mortality rates were similar in either group of treated patients as compared with the placebo group. The authors conclude that treatment with the study dose of methylprednisolone is indicated for acute spinal cord trauma, but only if it can be started within 8 hours of injury.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1727165     DOI: 10.3171/jns.1992.76.1.0023

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  86 in total

1.  Risks and benefits of preoperative high dose methylprednisolone in surgical patients: a systematic review.

Authors:  S Sauerland; M Nagelschmidt; P Mallmann; E A Neugebauer
Journal:  Drug Saf       Date:  2000-11       Impact factor: 5.606

2.  Methylprednisolone for acute spinal cord injury: not a standard of care.

Authors:  Herman Hugenholtz
Journal:  CMAJ       Date:  2003-04-29       Impact factor: 8.262

Review 3.  A systematic review of the effects of pharmacological agents on walking function in people with spinal cord injury.

Authors:  Antoinette Domingo; Abdulaziz A Al-Yahya; Yousif Asiri; Janice J Eng; Tania Lam
Journal:  J Neurotrauma       Date:  2012-02-29       Impact factor: 5.269

Review 4.  Medical treatments of acute spinal cord injury.

Authors:  W Young
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-08       Impact factor: 10.154

5.  Acute Treatment Options for Spinal Cord Injury.

Authors:  Manjunath Markandaya; Deborah M Stein; Jay Menaker
Journal:  Curr Treat Options Neurol       Date:  2012-02-03       Impact factor: 3.598

6.  Cochrane in CORR1: Steroids for Acute Spinal Cord Injury (Review).

Authors:  Nathan Evaniew; Marcel Dvorak
Journal:  Clin Orthop Relat Res       Date:  2016-01       Impact factor: 4.176

Review 7.  The challenge of recruitment for neurotherapeutic clinical trials in spinal cord injury.

Authors:  Andrew R Blight; Jane Hsieh; Armin Curt; James W Fawcett; James D Guest; Naomi Kleitman; Shekar N Kurpad; Brian K Kwon; Daniel P Lammertse; Norbert Weidner; John D Steeves
Journal:  Spinal Cord       Date:  2019-04-08       Impact factor: 2.772

8.  Significant correlation between cerebrospinal fluid nitric oxide concentrations and neurologic prognosis in incomplete cervical cord injury.

Authors:  Noboru Hosaka; Shinji Kimura; Akiyoshi Yamazaki; Xianjun Wang; Hiroshi Denda; Takui Ito; Toru Hirano; Naoto Endo
Journal:  Eur Spine J       Date:  2007-08-22       Impact factor: 3.134

9.  [Clinical experiences and results of high-dosage methylprednisolone therapy in spinal cord trauma 1991 to 1993].

Authors:  C Gäbler; R Maier
Journal:  Unfallchirurgie       Date:  1995-02

10.  [Spinal cord injury and syringomyelia].

Authors:  M Wolf; C H Fürstenberg; S Hähnel; M-A Weber
Journal:  Radiologe       Date:  2013-04       Impact factor: 0.635

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.